Literature DB >> 14707074

Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

Venu G Pillarisetty1, Alaap B Shah, George Miller, Joshua I Bleier, Ronald P DeMatteo.   

Abstract

The unique immunological properties of the liver may be due to the function of hepatic dendritic cells (DC). However, liver DC have not been well characterized because of the difficulty in isolating adequate numbers of cells for analysis. Using immunomagnetic bead and flow cytometric cell sorting, we compared freshly isolated murine liver and spleen CD11c+ DC. We found that liver DC are less mature, capture less Ag, and induce less T cell stimulation than spleen DC. Nevertheless, liver DC were able to generate high levels of IL-12 in response to CpG stimulation. We identified four distinct subtypes of liver DC based on the widely used DC subset markers CD8alpha and CD11b. Lymphoid (CD8alpha+CD11b-) and myeloid (CD8alpha-CD11b+) liver DC activated T cells to a similar degree as did their splenic DC counterparts but comprised only 20% of all liver DC. In contrast, the two more prevalent liver DC subsets were only weakly immunostimulatory. Plasmacytoid DC (B220+) accounted for 19% of liver DC, but only 5% of spleen DC. Our findings support the widely held notion that liver DC are generally weak activators of immunity, although they are capable of producing inflammatory cytokines, and certain subtypes potently activate T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707074     DOI: 10.4049/jimmunol.172.2.1009

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  91 in total

Review 1.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

Review 2.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 3.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

Review 4.  Regulatory T cells: present facts and future hopes.

Authors:  Christian Becker; Sabine Stoll; Tobias Bopp; Edgar Schmitt; Helmut Jonuleit
Journal:  Med Microbiol Immunol       Date:  2006-05-20       Impact factor: 3.402

5.  A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Authors:  Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

Review 6.  Mechanisms of drug-induced liver injury.

Authors:  Michael P Holt; Cynthia Ju
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 7.  Immune surveillance by the liver.

Authors:  Craig N Jenne; Paul Kubes
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

8.  Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury.

Authors:  Zubin M Bamboat; Vinod P Balachandran; Lee M Ocuin; Hebroon Obaid; George Plitas; Ronald P DeMatteo
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  DAP12 deficiency in liver allografts results in enhanced donor DC migration, augmented effector T cell responses and abrogation of transplant tolerance.

Authors:  O Yoshida; S Kimura; L Dou; B M Matta; S Yokota; M A Ross; D A Geller; A W Thomson
Journal:  Am J Transplant       Date:  2014-06-16       Impact factor: 8.086

Review 10.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.